1. Home
  2. ALCO vs PLYX Comparison

ALCO vs PLYX Comparison

Compare ALCO & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alico Inc.

ALCO

Alico Inc.

HOLD

Current Price

$37.90

Market Cap

293.7M

Sector

N/A

ML Signal

HOLD

PLYX

Polaryx Therapeutics Inc. Common Stock

N/A

Current Price

$5.37

Market Cap

262.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALCO
PLYX
Founded
1960
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.7M
262.3M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
ALCO
PLYX
Price
$37.90
$5.37
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
25.3K
1.9M
Earning Date
02-04-2026
01-01-0001
Dividend Yield
0.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.61
$2.20
52 Week High
$43.20
$8.15

Technical Indicators

Market Signals
Indicator
ALCO
PLYX
Relative Strength Index (RSI) 35.98 51.82
Support Level $37.14 $2.44
Resistance Level $38.40 $7.43
Average True Range (ATR) 1.41 1.11
MACD -0.25 0.26
Stochastic Oscillator 11.51 57.76

Price Performance

Historical Comparison
ALCO
PLYX

About ALCO Alico Inc.

Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.

About PLYX Polaryx Therapeutics Inc. Common Stock

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.

Share on Social Networks: